StreetInsider.com News Articles

Kymera Therapeutics (KYMR) PT Raised to $140 at JPMorgan

Wed, 02 Sep 2026 09:22:00 -0400

JPMorgan analyst Brian Cheng raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $140.00 (from $121.00) while maintaining a Overweight rating.

Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim

Mon, 31 Aug 2026 07:11:29 -0400

(Updated - August 31, 2026 7:11 AM EDT)

Guggenheim analyst Brad Canino raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $170.00 (from $135.00) while maintaining a Buy rating.

The analyst commented: "We have expanded our KT-621 (STAT6) market model to include several Th2 diseases and are increasing our Price Target to $170 (from $135) as we prepare for what the company could look like following Phase 2b atopic dermatitis data at year-end. If successful, we think these data are likely to be perceived by the market as dispositive; the Phase 3 will be rewarded a high probability-of success and KYMR's

Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim

Mon, 31 Aug 2026 07:11:29 -0400

(Updated - August 31, 2026 7:11 AM EDT)

Guggenheim analyst Brad Canino raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $170.00 (from $135.00) while maintaining a Buy rating.

Kymera Therapeutics (KYMR) PT Raised to $151 at Wells Fargo

Thu, 27 Aug 2026 07:14:32 -0400

Wells Fargo analyst Derek Archila raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $151.00 (from $116.00) while maintaining a Overweight rating.

TD Cowen Assumes Kymera Therapeutics (KYMR) at Buy

Sat, 22 Aug 2026 07:54:25 -0400

TD Cowen analyst Tyler Van Buren assumes coverage on Kymera Therapeutics (NASDAQ: KYMR) with a Buy rating.

For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.

Shares of Kymera Therapeutics closed at $119.80 yesterday.

Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926614.html

Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926614.html

Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.

Thu, 13 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260813/26922239.html

Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.

Thu, 13 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260813/26922239.html

Kymera Therapeutics (KYMR) PT Raised to $135 at Morgan Stanley

Thu, 06 Aug 2026 08:52:16 -0400

Morgan Stanley analyst Judah Frommer raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $135.00 (from $119.00) while maintaining a Overweight rating.

Kymera Therapeutics (KYMR) PT Raised to $139 at Barclays

Thu, 06 Aug 2026 04:19:59 -0400

Barclays analyst Eliana Merle raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $139.00 (from $133.00) while maintaining a Overweight rating.

Kymera Therapeutics (KYMR) PT Raised to $125 at Oppenheimer

Wed, 05 Aug 2026 14:57:11 -0400

(Updated - August 5, 2026 2:57 PM EDT)

Oppenheimer analyst Jeff Jones raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $125.00 (from $120.00) while maintaining a Outperform rating.

The analyst commented: "On Wednesday, KYMR reported 2Q26 results (press release, slides) and provided a business update. As previously reported, the Phase 2 readout for STAT-6 targeting KT-621 in AD has been pulled forward substantially, with results now anticipated before year-end. These remain the key focus with results anticipated to confirm the clinical profile for '621 and opening the door to multiple dermatological indications. It does not appear this acceleration will immediately

Kymera Therapeutics (KYMR) PT Raised to $125 at Oppenheimer

Wed, 05 Aug 2026 14:57:11 -0400

(Updated - August 5, 2026 2:57 PM EDT)

Oppenheimer analyst Jeff Jones raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $125.00 (from $120.00) while maintaining a Outperform rating.

Kymera Therapeutics (KYMR) PT Raised to $132 at Stifel

Wed, 05 Aug 2026 10:42:25 -0400

Stifel analyst Alex Thompson raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $132.00 (from $114.00) while maintaining a Buy rating.

Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c

Wed, 05 Aug 2026 07:30:21 -0400

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.62), $0.10 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $65 million versus the consensus estimate of $30.92 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

Form 10-Q Kymera Therapeutics, For: Jun 30

Wed, 05 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26870234.html

Form 10-Q Kymera Therapeutics, For: Jun 30

Wed, 05 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26870234.html

Form 8-K Kymera Therapeutics, For: Aug 05

Wed, 05 Aug 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26870183.html

Form 8-K Kymera Therapeutics, For: Aug 05

Wed, 05 Aug 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26870183.html

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Wed, 05 Aug 2026 07:00:00 -0400

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027

KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26

KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi

Well-capitalized with $1.5 billion in cash as of June

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Wed, 05 Aug 2026 07:00:00 -0400

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027

KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26

KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi

Well-capitalized with $1.5 billion in cash as of June

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Wed, 05 Aug 2026 07:00:00 -0400

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027

KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26

KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi

Well-capitalized with $1.5 billion in cash as of June

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Wed, 05 Aug 2026 07:00:00 -0400

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027

KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26

KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi

Well-capitalized with $1.5 billion in cash as of June

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Wed, 05 Aug 2026 07:00:00 -0400

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027

KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26

KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi

Well-capitalized with $1.5 billion in cash as of June

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Wed, 05 Aug 2026 07:00:00 -0400

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027

KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26

KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi

Well-capitalized with $1.5 billion in cash as of June